NCT04675996View on ClinicalTrials.gov

First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

March 24, 2023

Study Completion Date

March 24, 2023

Conditions
Solid Tumor
Interventions
DRUG

INT-1B3

60-min i.v. infusions twice per week in 21-day cycles

Trial Locations (4)

1000

Institut Jules Bordet, Brussels

Unknown

GZA (Gasthuiszusters Antwerpen), Antwerp

The Netherlands Cancer Institute, Amsterdam

Erasmus MC, Rotterdam

Sponsors

Lead Sponsor

InteRNA
All Listed Sponsors
lead

InteRNA

INDUSTRY

NCT04675996 - First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter